Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Bickers

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Cancer Prevention Research (Philadelphia, Pa.)|January 21, 2014
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndromeJean Y Tang, Albert S Chiou, Julian M Mackay-Wiggan, et al.
Oncotarget|September 29, 2015
Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndromeSandeep C Chaudhary, Xiuwei Tang, Aadithya Arumugam, et al.
The Lancet. Oncology|November 14, 2016
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trialJean Y Tang, Mina S Ally, Anita M Chanana, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 7, 2010
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and miceJean Y Tang, Michelle Aszterbaum, Mohammad Athar, et al.
Journal of the American Academy of Dermatology|December 15, 2025
Clinical practice guidelines for the management of basal cell carcinoma in Gorlin syndromeBrian A Cahn, Runze Zhang, Allie M Sidwell, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Cancer Prevention Research (Philadelphia, Pa.)|January 21, 2014
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndromeJean Y Tang, Albert S Chiou, Julian M Mackay-Wiggan, et al.
Oncotarget|September 29, 2015
Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndromeSandeep C Chaudhary, Xiuwei Tang, Aadithya Arumugam, et al.
The Lancet. Oncology|November 14, 2016
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trialJean Y Tang, Mina S Ally, Anita M Chanana, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 7, 2010
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and miceJean Y Tang, Michelle Aszterbaum, Mohammad Athar, et al.
Journal of the American Academy of Dermatology|December 15, 2025
Clinical practice guidelines for the management of basal cell carcinoma in Gorlin syndromeBrian A Cahn, Runze Zhang, Allie M Sidwell, et al.
Pageof 7